Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Queensland Health
Baxter
Citi
McKesson

Generated: September 19, 2019

DrugPatentWatch Database Preview

Patent: 8,129,114

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,129,114
Title:Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
Abstract: EGFR biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) measuring in the mammal the level of at least one biomarker selected from epiregulin and amphiregulin, (b) exposing a biological sample from the mammal to the EGFR modulator, and (c) following the exposing of step (b), measuring in the biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates an increased likelihood that the mammal will respond therapeutically to the method of treating cancer.
Inventor(s): Ford; Shirin K. (Princeton, NJ), Clark; Edwin A. (Pennington, NJ), Huang; Xin (Princeton, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:11/990,713
Patent Claims:see list of patent claims

Details for Patent 8,129,114

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18 ➤ Sign Up Bristol-Myers Squibb Company (Princeton, NJ) 2025-08-24 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27 ➤ Sign Up Bristol-Myers Squibb Company (Princeton, NJ) 2025-08-24 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27 ➤ Sign Up Bristol-Myers Squibb Company (Princeton, NJ) 2025-08-24 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27 ➤ Sign Up Bristol-Myers Squibb Company (Princeton, NJ) 2025-08-24 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Citi
Cipla
Fish and Richardson
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.